These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 21144476)

  • 1. [The histaminergic system: a target for innovative treatments of cognitive deficits].
    Motawaj M; Burban A; Davenas E; Gbahou F; Faucard R; Morisset S; Arrang JM
    Therapie; 2010; 65(5):415-22. PubMed ID: 21144476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of brain histaminergic neurotransmission: a mechanism for cognitive effects of memantine in Alzheimer's disease.
    Motawaj M; Burban A; Davenas E; Arrang JM
    J Pharmacol Exp Ther; 2011 Feb; 336(2):479-87. PubMed ID: 21057059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The histamine H3 receptor as a therapeutic drug target for CNS disorders.
    Gemkow MJ; Davenport AJ; Harich S; Ellenbroek BA; Cesura A; Hallett D
    Drug Discov Today; 2009 May; 14(9-10):509-15. PubMed ID: 19429511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Constitutive activity of the histamine H3 receptor.
    Arrang JM; Morisset S; Gbahou F
    Trends Pharmacol Sci; 2007 Jul; 28(7):350-7. PubMed ID: 17573125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders.
    Parmentier R; Anaclet C; Guhennec C; Brousseau E; Bricout D; Giboulot T; Bozyczko-Coyne D; Spiegel K; Ohtsu H; Williams M; Lin JS
    Biochem Pharmacol; 2007 Apr; 73(8):1157-71. PubMed ID: 17288995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of betahistine at histamine H3 receptors: mixed inverse agonism/agonism in vitro and partial inverse agonism in vivo.
    Gbahou F; Davenas E; Morisset S; Arrang JM
    J Pharmacol Exp Ther; 2010 Sep; 334(3):945-54. PubMed ID: 20530654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in histamine H3 receptor antagonists/inverse agonists.
    Łazewska D; Kieć-Kononowicz K
    Expert Opin Ther Pat; 2010 Sep; 20(9):1147-69. PubMed ID: 20716022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneity of histaminergic neurons in the tuberomammillary nucleus of the rat.
    Giannoni P; Passani MB; Nosi D; Chazot PL; Shenton FC; Medhurst AD; Munari L; Blandina P
    Eur J Neurosci; 2009 Jun; 29(12):2363-74. PubMed ID: 19490084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic potential of histamine H3 receptor antagonists in dementias.
    Chazot PL
    Drug News Perspect; 2010 Mar; 23(2):99-103. PubMed ID: 20369074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histamine and schizophrenia.
    Arrang JM
    Int Rev Neurobiol; 2007; 78():247-87. PubMed ID: 17349864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF levels of the histamine metabolite tele-methylhistamine are only slightly decreased in Alzheimer's disease.
    Motawaj M; Peoc'h K; Callebert J; Arrang JM
    J Alzheimers Dis; 2010; 22(3):861-71. PubMed ID: 20858978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders.
    Passani MB; Lin JS; Hancock A; Crochet S; Blandina P
    Trends Pharmacol Sci; 2004 Dec; 25(12):618-25. PubMed ID: 15530639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. H3 receptor antagonists/inverse agonists as anti-obesity agents.
    Hancock AA
    Curr Opin Investig Drugs; 2003 Oct; 4(10):1190-7. PubMed ID: 14649210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential of histaminergic compounds in the treatment of addiction and drug-related cognitive disorders.
    Alleva L; Tirelli E; Brabant C
    Behav Brain Res; 2013 Jan; 237():357-68. PubMed ID: 23000530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The histamine H(3) receptor: a target for new drugs].
    Arrang JM
    Ann Pharm Fr; 2003 May; 61(3):173-84. PubMed ID: 12714930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system.
    Witkin JM; Nelson DL
    Pharmacol Ther; 2004 Jul; 103(1):1-20. PubMed ID: 15251226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease.
    Brioni JD; Esbenshade TA; Garrison TR; Bitner SR; Cowart MD
    J Pharmacol Exp Ther; 2011 Jan; 336(1):38-46. PubMed ID: 20864505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropathologic changes in Alzheimer's disease: potential targets for treatment.
    Wenk GL
    J Clin Psychiatry; 2006; 67 Suppl 3():3-7; quiz 23. PubMed ID: 16649845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High constitutive activity of native H3 receptors regulates histamine neurons in brain.
    Morisset S; Rouleau A; Ligneau X; Gbahou F; Tardivel-Lacombe J; Stark H; Schunack W; Ganellin CR; Schwartz JC; Arrang JM
    Nature; 2000 Dec; 408(6814):860-4. PubMed ID: 11130725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular imaging of histamine receptors in the human brain].
    Tashiro M; Yanai K
    Brain Nerve; 2007 Mar; 59(3):221-31. PubMed ID: 17370648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.